NATURAL PHARMA
ActiveThe computed 12-month bankruptcy probability of NATURAL PHARMA is 3.4% (moderate). The 2025 annual accounts show equity of €285k and a net result of €63k. Equity is growing by ~23.5% per year across the filed fiscal years. Its solvency ranks better than 56% of 10242 sector peers (fiscal year 2025). The company has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
86
/ 100
Excellent▲ +3 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency83▲+13
Growth78=
Stability100
Bankruptcy probability, 12 months
3.4%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €25k at 30 days acceptable
Liquidity ample (current ratio 1.79 against 1.63 in 2024), but 56.9% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
43.1%
Return on assets
9.5%
Age of the figures
8 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 6 filingsDeviation from the deadline
2025
31 d late
2024
31 d late
2023
14 d late
2022
6 d early
2021
73 d late
2020
3 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
14-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€63k▼ 22.0%
2024 · €80k
2020: €3k
2021: €52k
2022: €123k
2023: €106k
2024: €80k
2020 → 2025
Working capital
€216k▲ 32.6%
2024 · €163k
2020: €77k
2021: €85k
2022: €199k
2023: €229k
2024: €163k
2020 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€85k-€208k▲ 145%€267k▲ 28.4%€223k▼ 16.7%€285k▲ 28.2%
Operating result€75k-€159k▲ 112%€141k▼ 11.5%€109k▼ 22.7%€87k▼ 20.4%
Net result€52k-€123k▲ 136%€106k▼ 13.9%€80k▼ 24.3%€63k▼ 22.0%
Result per fiscal year
Operating resultNet result
The operating result has fallen three years in a row; 2025 is 20% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €663k
Fixed assets
€174k▼ 13.6%
Current assets
€489k▲ 15.4%
Equity and liabilities €663k
Equity
€285k▲ 28.2%
Debt
€377k▼ 6.2%
The debt ratio falls from 64.4% to 56.9%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€136k▼
2024 · €150k
Cash flow
€112k▼
2024 · €121k
Solvency
43.1%▲
2024 · 35.6%
Current ratio
1.79▲
2024 · 1.63
Quick ratio
1.30▲
2024 · 1.15
Debt / equity
1.32▼
2024 · 1.81
ROE
22.0%▼
2024 · 36.1%
ROA
9.5%▼
2024 · 12.9%
Interest coverage
20.81▼
2024 · 22.48
Debt
€377k▼
2024 · €402k
Debt ≤ 1 year
€273k▲
2024 · €261k
Debt > 1 year
€105k▼
2024 · €142k
Income taxes
€19k▼
2024 · €23k
Staff costs
€104k▼
2024 · €136k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€625k€663k▲
Fixed assets21/28€201k€174k▼
Intangible fixed assets21€93k€74k▼
Tangible fixed assets22/27€108k€100k▼
Plant, machinery and equipment23€1k€13k▲
Furniture and vehicles24€37k€26k▼
Other tangible fixed assets26€70k€61k▼
Current assets29/58€424k€489k▲
Stocks and contracts in progress3€124k€135k▲
Stocks30/36€124k€135k▲
Amounts receivable within one year40/41€84k€116k▲
Trade receivables40€77k€104k▲
Other amounts receivable41€7k€11k▲
Cash at bank and in hand54/58€213k€236k▲
Deferred charges and accrued income490/1€3k€2k▼
Equity and liabilities
Total equity and liabilities10/49€625k€663k▲
Equity10/15€223k€285k▲
Contributions10/11€30k€30k=
Profit (loss) carried forward14€193k€255k▲
Amounts payable17/49€402k€377k▼
Amounts payable after more than one year17€142k€105k▼
Financial debts170/4€142k€105k▼
Amounts payable within one year42/48€261k€273k▲
Current portion of amounts payable after more than one year42€36k€37k▲
Trade debts44€147k€158k▲
Suppliers440/4€147k€158k▲
Taxes, remuneration and social security45€48k€42k▼
Taxes450/3€30k€13k▼
Remuneration and social security454/9€18k€29k▲
Other amounts payable47/48€29k€36k▲
Income statement
Code20242025
Remuneration, social security and pensions62€136k€104k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€41k€49k▲
Other operating charges640/8€3k€1k▼
Gross operating margin9900€289k€241k▼
Operating profit (loss)9901€109k€87k▼
Financial income75/76B€1k€997▼
Recurring financial income75€1k€997▼
Financial charges65/66B€7k€7k▼
Recurring financial charges65€7k€7k▼
Profit (loss) for the period before taxes9903€104k€81k▼
Income taxes67/77€23k€19k▼
Profit (loss) for the period9904€80k€63k▼
Profit (loss) for the period to be appropriated9905€80k€63k▼
Appropriation of the result
Profit (loss) to be appropriated9906€318k€255k▼
Profit (loss) brought forward from the previous period14P€237k€193k▼
Profit to be distributed694/7€125k€0▼
Return on contributions (dividend)694€125k€0▼
Social balance
Average headcount (FTE)90870.0-
The notes to these accounts (18 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 31 days late
2025
31-08
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 31 days late
2024
14-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 14 days late
2023
25-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Highest result since 2020net €123k ▲136%
Operating result €159k, net result €123k, both a record.
31-12
Financial
Equity above €200kEq €208k ▲145%
3 profitable years in a row build equity to €208k.
12-10
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 73 days late
2021
28-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Brussel · 2 establishment units since 2019
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Oorlogskruisenlaan 941120 BrusselGround area
9,210 m²
Building footprint
1,191 m²
Volume, LiDAR
12,691 m³
3 parcels, Brussels, Flanders · tallest building 20.1 m, ±5 floors. Linked by address, not a title deed.
2 establishment units
NATURAL PHARMA
since 20192.300.883.748
NATURAL PHARMA
since 20252.381.181.338
3 parcels
Flanders
1
(33.3%)
Brussels
2
(66.7%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21819D0090/00P000 | Brussels | 8,062 m² | 1 · 656 m² | 18.0 m · 4 fl. |
| 23645C0028/00R000 | Flanders | 610 m² | 1 · 121 m² | 7.8 m · 2 fl. |
| 21819D0138/00M004 | Brussels | 538 m² | 1 · 415 m² | 20.1 m · 5 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 2
3 of 3 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMACIE CITY
BE 0817.122.357
Schaarbeek · Eq €285k
Pharmacie BORN
BE 0748.996.089
Flémalle · Eq €286k
APOTHEEK CALLENS
BE 0479.110.813
Gent · Eq €286k
Apotheek Colpaert
BE 0845.626.204
Harelbeke · Eq €285k
APOTHEEK TILLEGEM
BE 0558.938.051
Brugge · Eq €286k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 3,504 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded14-11-2019
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 6 filingsAddress and cadastre registers
Data from official sources, last processed on 14-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
3 entriesE-mail:natural.pharma@outlook.com
Phone:026277717
Phone:022415887